Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'Senseless violence' erupts at Christmas tree lighting; 4 injured - 2Why the Houthis waited until now to strike
- 3Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- 4Palestinian leader Abbas says elections only after Gaza war ends
- 5Vote In favor of Your Favored Shimmering Water
- Track down Your Optimal Conservative Vehicle: Famous Brands to Consider
- These 45 exoplanets may be the best places to search for alien life
- What are parents to do as doctors clash with Trump administration over vaccines?
- Was This Driver Simply Having Some good times Or Behaving Like An Ass?
- Vote In favor of Your Favored Kind Of Bites
- Vote In favor of Your Number one Game Control center
- Tech for Wellbeing: Applications and Devices for a Better You
- Photos of amputees in Gaza, struggling to survive after losing limbs to Israeli airstrikes
- Behind every perfect holiday memory is a mom on the brink
